Literature DB >> 26446888

Development of single-chain variable fragments (scFv) against influenza virus targeting hemagglutinin subunit 2 (HA2).

Tai-Wei Li1, Shu-Fang Cheng1, Yen-Tzu Tseng1, Yu-Chih Yang2, Wen-Chun Liu3, Sheng-Cyuan Wang1, Mei-Ju Chou1, Yu-Jen Lin1, Yueh Wang4, Pei-Wen Hsiao2, Suh-Chin Wu3, Ding-Kwo Chang5.   

Abstract

Influenza A viruses (IAV) are widespread in birds and domestic poultry, occasionally causing severe epidemics in humans and posing health threats. Hence, the need to develop a strategy for prophylaxis or therapy, such as a broadly neutralizing antibody against IAV, is urgent. In this study, single-chain variable fragment (scFv) phage display technology was used to select scFv fragments recognizing influenza envelope proteins. The Tomlinson I and J scFv phage display libraries were screened against the recombinant HA2 protein (rHA2) for three rounds. Only the third-round elution sample of the Tomlinson J library showed high binding affinity to rHA2, from which three clones (3JA18, 3JA62, and 3JA78) were chosen for preparative-scale production as soluble antibody by E. coli. The clone 3JA18 was selected for further tests due to its broad affinity for influenza H1N1, H3N2 and H5N1. Simulations of the scFv 3JA18-HA trimer complex revealed that the complementarity-determining region of the variable heavy chain (VH-CDR2) bound the stem region of HA. Neutralization assays using a peptide derived from VH-CDR2 also supported the simulation model. Both the selected antibody and its derived peptide were shown to suppress infection with H5N1 and H1N1 viruses, but not H3N2 viruses. The results also suggested that the scFvs selected from rHA2 could have neutralizing activity by interfering with the function of the HA stem region during virus entry into target cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26446888     DOI: 10.1007/s00705-015-2625-6

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  8 in total

Review 1.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

2.  Designing antibody against highly conserved region of dengue envelope protein by in silico screening of scFv mutant library.

Authors:  Abhishek Singh Rathore; Animesh Sarker; Rinkoo Devi Gupta
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

3.  Novel single-chain antibodies against highly conserved epitopes in the hemagglutinin of influenza A viruses: Promising agents for universal therapies.

Authors:  Samaneh Alizadeh; Setareh Moazen; Seyed Nooreddin Faraji; Afagh Moattari; Foroogh Nejatollahi
Journal:  Iran J Basic Med Sci       Date:  2021-01       Impact factor: 2.699

4.  Characterization of an intracellular humanized single-chain antibody to matrix protein (M1) of H5N1 virus.

Authors:  He Sun; Guangmou Wu; Jiyuan Zhang; Yu Wang; Yue Qiu; Hongyang Man; Guoli Zhang; Zehong Li; Yuhuan Yue; Yuan Tian
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

Review 5.  Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases.

Authors:  Hao-Ming Xu; Wen-Min Xu; Long Zhang
Journal:  Int J Clin Pract       Date:  2022-10-03       Impact factor: 3.149

6.  Single Chain Fragment Variable (scFv) Antibodies Targeting the Spike Protein of Porcine Epidemic Diarrhea Virus Provide Protection against Viral Infection in Piglets.

Authors:  Fanqing Zhang; Yuxue Chen; Yong Ke; Lei Zhang; Bo Zhang; Liang Yang; Jianguo Zhu
Journal:  Viruses       Date:  2019-01-14       Impact factor: 5.048

7.  In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus.

Authors:  Yejin Jang; Jin Soo Shin; Joo-Youn Lee; Heegwon Shin; Sang Jick Kim; Meehyein Kim
Journal:  Viruses       Date:  2020-05-25       Impact factor: 5.048

8.  Expression, Purification, and Characterization of Anti-Zika virus Envelope Protein: Polyclonal and Chicken-Derived Single Chain Variable Fragment Antibodies.

Authors:  Pharaoh Fellow Mwale; Chi-Hsin Lee; Liang-Tzung Lin; Sy-Jye Leu; Yun-Ju Huang; Liao-Chun Chiang; Yan-Chiao Mao; Yi-Yuan Yang
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.